Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT02929771 Completed - Cancer Clinical Trials

Using Virtual Reality to Reduce Procedural Pain in Children With Cancer

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

This study will assess the impact of virtual reality (VR) in decreasing procedural pain related to subcutaneous port (SCP) access in children with cancer. The study is a pilot-randomized controlled trial (RCT) using a cross-over design that will provide us with detailed information on the feasibility of implementing our trial protocol in a future multi-center RCT as well as preliminary estimate of VR treatment effect on children with cancer undergoing SCP access, including child and parent factors potentially associated with VR distraction treatment efficacy.

NCT ID: NCT02929108 Completed - Pain Clinical Trials

ACCESS (Access for Cancer Caregivers for Education and Support for Shared Decision Making)

ACCESS
Start date: April 1, 2017
Phase: N/A
Study type: Interventional

The project will test the effect of educating and supporting family caregivers of hospice cancer patients on their active participation in shared decision making in the plan of care for their patients.

NCT ID: NCT02925000 Completed - Cancer Clinical Trials

Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

Start date: June 19, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/IIa, Open label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy.

NCT ID: NCT02922647 Completed - Cancer Clinical Trials

Suprapubic Versus Transurethral Catheterization After Rectal Resection With Low Anastomosis for Cancer in Males

GRECCAR10
Start date: October 14, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the urinary tract infection rate on the four postoperative day between the 2 groups of patients who have undergone total mesorectal excision for cancer and low anastomosis, with either suprapubic or transurethral catheterization.

NCT ID: NCT02921919 Completed - Cancer Clinical Trials

Open-Label Extension and Safety Study of Talazoparib

Start date: November 8, 2016
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

NCT ID: NCT02915471 Completed - Cancer Clinical Trials

Virtual Peer-to-Peer (VP2P) Support Mentoring for Adolescents With Cancer

Start date: August 2016
Phase: N/A
Study type: Interventional

The overall aim of this research program is to develop and examine the impact of a Cancer virtual peer-to-peer (VP2P) Support Program on health-related quality of life (HRQL) in adolescents with cancer (AWC). In the current proposal, the feasibility of trialing the Skype-based VP2P program providing peer-support from mentors and the magnitude of program effect estimates will be evaluated in a pilot randomized control trial (RCT). This pilot RCT will enable us to refine the program and determine the appropriate sample size for a future large-scale RCT, which will compare the effectiveness of VP2P to a waitlist control group at a major Children's Oncology Group- affiliated centers in Canada and the United States.

NCT ID: NCT02912273 Completed - Cancer Clinical Trials

Optimizing Fall-risk Prediction in Older Adults With Cancer

Start date: October 12, 2016
Phase:
Study type: Observational

To establish the optimal strategy of fall-risk assessment to predict falls in older adults receiving cancer therapy.

NCT ID: NCT02906592 Completed - Cancer Clinical Trials

Using a Geriatric Oncology Assessment to Link With Services

GOAL
Start date: January 2017
Phase: N/A
Study type: Observational

The objective of this study is to implement a brief geriatric oncology assessment (GOA) in a community-based oncology clinic, the Scotland Cancer Treatment Center - a clinic within the Duke Cancer Network, located in the rural, low resource Scotland County community of North Carolina. Secondly, the investigators will evaluate the effectiveness of the brief GOA by comparing historical and post-GOA service referral patterns and adherence to planned cancer therapy. For this study, the investigators will prospectively enroll up to 60 patients who have been diagnosed and/or treated for cancer to complete the brief GOA. In addition to these 60 patients, the investigators will also conduct retrospective chart reviews on 120 patients that would be eligible for this study to evaluate past referral patterns. Eligible and consented patients will complete the brief GOA at the Scotland Cancer Treatment Center alongside their normal clinic appointment. The investigators will assess impact on the healthcare system by evaluating referral patterns (i.e., how many, what type of services) using the brief GOA data and EHR data. The study value includes the possibility for recognition and access to additional health care referrals if needed.

NCT ID: NCT02904226 Completed - Cancer Clinical Trials

JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

ICONIC
Start date: August 2016
Phase: Phase 1/Phase 2
Study type: Interventional

JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

NCT ID: NCT02902627 Completed - Pain Clinical Trials

Pain in Oncolgy: Evaluation of a Non Invasive Monitoring Device (ANI). A Monocentric Prospective Study

ANIONCO
Start date: August 2012
Phase: N/A
Study type: Interventional

l'ANI (Analgesia Nociception Index The main objective of the research is to estimate the Analgesia Nociception Index (ANI) as a parameter giving the possibility of measuring the pain in painful metastatic cancer. The parameter ANI is compared with visual analogical scale (VAS) score.